REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

Inclusion Criteria: * Understands the study procedures and can give signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Male or female ≥18 years of age. * Is suspected of having cardiac amyloidosis and is undergoing or will undergo a diagnostic evaluation for cardiac amyloidosis (e.g., echocardiogram \[ECHO\], cardiac magnetic resonance imaging \[CMR\], bone-avid tracer cardiac single-photon emission computerized tomography (SPECT), extracardiac biopsy, or endomyocardial biopsy \[EMB\]). Participants may be enrolled before or during their diagnostic evaluation for cardiac amyloidosis. * Able to undergo PET/CT imaging as part of the study, including ability to lie supine for approximately 1 hour. * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 30 days after administration of I-124 evuzamitide. * For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm during the treatment period and for at least 120 days after the last dose of study intervention. Exclusion Criteria: * Established diagnosis of cardiac amyloidosis. * Established diagnosis of systemic amyloidosis with known organ involvement (e.g., renal AL or ATTR peripheral neuropathy). P…